About Celimmune
Celimmune is a company based in Bethesda (United States) founded in 2015 was acquired by Amgen in June 2017. Celimmune offers products and services including Biologic Medicines and Clinical Trials Services. Celimmune operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Bethesda, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amgen Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Celimmune
Celimmune offers a comprehensive portfolio of products and services, including Biologic Medicines and Clinical Trials Services.
Treat serious diseases using innovative biologic technologies
Optimize trials for faster medicine development
Funding Insights of Celimmune
Detailed funding history for Celimmune
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Celimmune
Celimmune has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceutical products for treating multiple diseases
|
Locked | Locked | Locked |
Investor details for Celimmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Celimmune
Investment portfolio details for Celimmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Celimmune
Detailed financials for Celimmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Celimmune Comparisons
Peer comparison for Celimmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Celimmune
Celimmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Celimmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Celimmune
Complete news archive for Celimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celimmune
Celimmune was founded in 2015.
Celimmune is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Celimmune was founded in 2015 in Bethesda, United States, as a clinical-stage biotechnology firm. Focus is placed on therapies for celiac disease and other immune disorders, utilizing a rapid clinical development approach. The lead candidate, AMG 714an anti-IL-15 monoclonal antibody licensed from Amgenis evaluated in phase-2 trials for non-responsive and refractory celiac disease. Development also includes iVYLISA GIP, a gluten immunoassay for diet management and clinical trial support.
Celimmune's top competitors include argenx, BioNTech and Generate Biomedicines.
Celimmune offers Biologic Medicines and Clinical Trials Services.
Celimmune has 1 investor. Key investors include Amgen.